- Home
- CDIO vs ENSC Comparison
CDIO vs ENSC Comparison
Compare CDIO & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDIO
- ENSC
- Stock Information
- Founded
- CDIO 2017
- ENSC 2003
- Country
- CDIO United States
- ENSC United States
- Employees
- CDIO N/A
- ENSC N/A
- Industry
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- CDIO Health Care
- ENSC Health Care
- Exchange
- CDIO Nasdaq
- ENSC Nasdaq
- Market Cap
- CDIO 6.4M
- ENSC 5.2M
- IPO Year
- CDIO N/A
- ENSC N/A
- Fundamental
- Price
- CDIO $4.39
- ENSC $2.24
- Analyst Decision
- CDIO Buy
- ENSC
- Analyst Count
- CDIO 1
- ENSC 0
- Target Price
- CDIO $60.00
- ENSC N/A
- AVG Volume (30 Days)
- CDIO 41.0K
- ENSC 92.0K
- Earning Date
- CDIO 08-11-2025
- ENSC 08-13-2025
- Dividend Yield
- CDIO N/A
- ENSC N/A
- EPS Growth
- CDIO N/A
- ENSC N/A
- EPS
- CDIO N/A
- ENSC N/A
- Revenue
- CDIO $19,902.00
- ENSC $6,224,081.00
- Revenue This Year
- CDIO $1,434.82
- ENSC N/A
- Revenue Next Year
- CDIO $4,661.91
- ENSC $1,381.48
- P/E Ratio
- CDIO N/A
- ENSC N/A
- Revenue Growth
- CDIO N/A
- ENSC 256.35
- 52 Week Low
- CDIO $3.22
- ENSC $1.62
- 52 Week High
- CDIO $53.10
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- CDIO 50.34
- ENSC 52.50
- Support Level
- CDIO $4.11
- ENSC $2.08
- Resistance Level
- CDIO $4.73
- ENSC $2.27
- Average True Range (ATR)
- CDIO 0.33
- ENSC 0.17
- MACD
- CDIO 0.10
- ENSC 0.01
- Stochastic Oscillator
- CDIO 65.03
- ENSC 62.79
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.